Your browser doesn't support javascript.
loading
Systematic evaluation for efficacy of tripterygium glycosides in treating diabetic nephropathy stage IV / 中国中药杂志
China Journal of Chinese Materia Medica ; (24): 3100-3109, 2015.
Artigo em Chinês | WPRIM | ID: wpr-284792
ABSTRACT
To systematically evaluate the efficacy and safety of tripterygium glycosides (TG) combined with ACEI/ARB preparation in treating diabetic nephropathy stage IV. The computer retrievals were made in Cochrane Libarary, PubMed, Embase, SCI, Sinnomed, CNKI, Chinainfo and VIP, and hand retrievals were conducted for meeting and academic papers (updated to December 30, 2014), in order to collect randomized controlled trials and quasi-randomized control trials for TG combined with ACEI/ARB preparation in treating diabetic nephropathy stage IV and set the literature inclusion and elimination standards. Eligible literatures were included and evaluated according to standards in Cochrane Handbook. RevMan 5.3 and Stata 12.0 were used for a Meta-analysis. A total of 13 randomized controlled trials and quasi-randomized control trials involving 1119 patients with diabetic nephropathy were included. The Meta analysis result showed that compared with the control group, the combination group showed better effects in reducing the 24-hour urinary protein [MD = -0.84, 95% CI (-1.02, -0.66)], raising albumin [SMD = 0.98, 95% CI (0.81, 1.16)], the total efficiency [OR = 4.23, 95% CI (2.77, 6.46)] and the significant efficiency [OR = 5.35, 95% CI (2.70, 10.60)], with no statistical difference in Serum Creatinine between Both groups [MD = -0.82, 95% CI (-4.30, 2.66), P = 0.64]. However, the risk of adverse reactions increased by 7% [RD = 0.07, 95% CI (0.03, 0.12)]. The Egger's test showed no publication bias. Tripterygium Glycosides combined with ACEI/ARB in treating diabetic nephropathy stage IV is supper than the single administration of ACEI/ARB, with a good prospect in clinical application. Nevertheless, due to the small-size and low-quality samples in this study, more high-quality and large sample-size randomized controlled trials shall be conducted to verify the findings.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Química / Tripterygium / Nefropatias Diabéticas / Tratamento Farmacológico / Quimioterapia Combinada / Antagonistas de Receptores de Angiotensina / Glicosídeos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica Limite: Humanos Idioma: Chinês Revista: China Journal of Chinese Materia Medica Ano de publicação: 2015 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Química / Tripterygium / Nefropatias Diabéticas / Tratamento Farmacológico / Quimioterapia Combinada / Antagonistas de Receptores de Angiotensina / Glicosídeos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica Limite: Humanos Idioma: Chinês Revista: China Journal of Chinese Materia Medica Ano de publicação: 2015 Tipo de documento: Artigo